Solid Biosciences is the lead sponsor of 6 current clinical trials in our USA, UK and EU (CTIS) registers. 4 are recruiting patients now. The most common phase is Phase 1/2. The most-studied condition is Duchenne Muscular Dystrophy.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
NCT06138639 · ClinicalTrials.gov ↗ · Duchenne Muscular Dystrophy
|
Phase 1/2 | Recruiting | 2024-05 | UK, USA |
|
A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
NCT07180355 · ClinicalTrials.gov ↗ · Friedreich's Ataxia (FA)
|
Phase 1 | Recruiting | 2025-10 | USA |
|
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
NCT07160634 · ClinicalTrials.gov ↗ · Duchenne Muscular Dystrophy
|
Phase 3 | Recruiting | 2025-10 | USA |
|
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
NCT07148089 · ClinicalTrials.gov ↗ · Catecholaminergic Polymorphic Ventricular Tachycardia
|
Phase 1 | Recruiting | 2026-02 | USA |
|
Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
NCT03368742 · ClinicalTrials.gov ↗ · Duchenne Muscular Dystrophy
|
Phase 1/2 | Active, closed | 2017-12 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System with Solid Biosciences as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Countries |
|---|---|---|---|
|
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy
2025-522949-22-00 · CTIS ↗ · Musculoskeletal Diseases
|
Phase 3 | Authorised | Spain, Netherlands, France + 3 more |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 5 | 4 |
| Clinical trials in UK | 1 | 1 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Sarepta Therapeutics | 6 |
| Italfarmaco | 3 |
| NS Pharma | 3 |
| REGENXBIO | 3 |
| Edgewise Therapeutics | 2 |
| Wave Life Sciences USA | 2 |
Sponsors with the most current trials registered for this condition.
Solid Biosciences is the lead sponsor of 5 current trials on ClinicalTrials.gov in our USA and UK registers, and 1 authorised or ongoing trial in the EU register (CTIS), as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of its 5 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.